Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)

Acadia Pharmaceuticals (ACAD) reported fourth-quarter 2024 earnings of 17 cents per share, missing the Zacks Consensus Estimate of 19 cents. The reported figure has been adjusted for the net proceeds from the one-time sale of its Rare Pediatric Disease Priority Review Voucher. ACAD reported GAAP earnings per share of 86 cents in the quarter under review.  In the year-ago quarter, the company had reported earnings of 28 cents per share. See the Zacks Earnings Calendar to stay ahead of market-making news. Aca ...